Skip to main content
Clinical Trials/NCT06491615
NCT06491615
Recruiting
Not Applicable

National Ophthalmic Genotyping and Phenotyping Network, Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

National Eye Institute (NEI)2 sites in 1 country1,000 target enrollmentJuly 12, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Inherited Ophthalmic Diseases
Sponsor
National Eye Institute (NEI)
Enrollment
1000
Locations
2
Primary Endpoint
To expand the current eyeGENE data repository with targeted participant accrual.
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

Background:

The eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includes genotypic and phenotypic data, imaging, and a corresponding biobank of DNA samples from people with a variety of eye diseases. Since 2007 this registry has been helping researchers learn more about the genetic sources for many inherited eye diseases. These findings helped them create better treatments. Now researchers want to expand eyeGENE (Registered Trademark) to include more people for certain eye diseases.

Objective: To collect information and DNA samples for the study of eye diseases.

  • Primary objective

    --To expand the current eyeGENE (Registered Trademark) data repository with targeted participant accrual

  • Secondary objectives

    • To enhance recruitment for clinical trials and investigations in inherited eye diseases

      • To establish genotype-phenotype correlations for rare eye diseases

Eligibility:

People of any age with certain eye diseases. These can include aniridia; Best disease; blue-cone monochromacy; corneal dystrophy; and disorders of pigmentation, such as albinism. Relatives unaffected by the eye disease of interest may also be needed.

Design:

Researchers will select participants based on their diagnosis. The data may include images and test results from eye exams.

Participants will provide a sample of saliva. They will receive a kit with written instructions. They will spit in a tube and mail it to the NIH.

Participants may be asked to provide a blood sample. The blood may be drawn at the NIH or at a local clinic.

The eyeGENE (Registered Trademark) repository will offer researchers data about the participants eye conditions. The data may include pictures of their eyes, results of the genetic testing, and history of other diseases. Researchers will be able to see data such as age and gender, but they will not see names, dates of birth, or contact information.

Detailed Description

STUDY DESCRIPTION: Molecular genetics has revolutionized the diagnosis and treatment of inherited eye diseases. Progress in research on inherited eye disease is augmented by the availability of patient DNA coupled to phenotypic information. To expand the current eyeGENE (Registered Trademark) data repository, participants will be accrued from targeted rare and ultra-rare disease populations. OBJECTIVES: Primary Objective: -To expand the current eyeGENE (Registered Trademark) data repository with targeted participant accrual Secondary Objectives: * To enhance recruitment for clinical trials and investigations in inherited eye diseases * To establish genotype-phenotype correlations for rare eye diseases

Registry
clinicaltrials.gov
Start Date
July 12, 2024
End Date
June 27, 2054
Last Updated
8 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

To expand the current eyeGENE data repository with targeted participant accrual.

Time Frame: 30 years

To expand the current eyeGENE data repository with targeted participant accrual.

Secondary Outcomes

  • To enhance recruitment for clinical trials and investigations in inherited eye diseases.(30 years)
  • To establish genotype-phenotype correlations for rare eye diseases.(30 years)

Study Sites (2)

Loading locations...

Similar Trials